Lead Product(s) : Serlopitant
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant
Details : Study MTI-105 and Study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2020
Lead Product(s) : Serlopitant
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Serlopitant
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Menlo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger
Details : The combined company already has an approved, commercial-stage product, AMZEEQ™, and several late-stage product candidates.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2020
Lead Product(s) : Serlopitant
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Menlo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
LOOKING FOR A SUPPLIER?